CEL-SCI (CVM) Receives Regulatory Clearance To Expand CEL-SCI’S Phase 3 Head And Neck Cancer Trial Into Austria
7/8/2014 6:39:05 AM
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE MKT:CVM) today announced that it has received regulatory clearance from the Austrian Federal Office for Safety in Health Care to begin patient enrollment in the Company’s Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection). Austria is the 14th country to participate in CEL-SCI’s trial which is already active in numerous clinics around the world.
CEL-SCI’s Phase III trial is assessing the use of the Company’s Multikine immunotherapy as a first line treatment for patients diagnosed with advanced primary head and neck cancer, prior to standard of care, which involves surgery, chemotherapy, and/or radiation therapy. If approved for use following completion of CEL-SCI's clinical development program for head and neck cancer, Multikine would be a different type of therapy in the fight against cancer; one that appears to have the potential to work with the body's natural immune system in the fight against tumors.
Help employers find you! Check out all the jobs and post your resume.
comments powered by